Press Releases May 1, 2026 06:45 AM

AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for First Quarter Fiscal 2026 Results

AirSculpt Technologies schedules Q1 2026 earnings release, details upcoming investor conferences and webcast access.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
AIRS

AirSculpt Technologies, a NASDAQ-listed company specializing in premium body contouring procedures, announced it will report its first quarter fiscal 2026 earnings on May 8, 2026, before market open. The company will follow the release with a conference call and webcast. Additionally, AirSculpt will participate in two investor conferences later in May, hosting presentations and meetings with investors.

AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for First Quarter Fiscal 2026 Results
AIRS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • AirSculpt will release first quarter 2026 financial results on May 8, 2026, before market open.
  • The company will conduct a conference call and webcast for investors to discuss results and outlook.
  • AirSculpt will participate in Wolfe Research Global Consumer Growth Conference and LD Micro Invitational with presentations and investor meetings.
  • The company operates in the cosmetic medical procedure sector, impacting the healthcare and consumer discretionary markets.

MIAMI BEACH, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report first quarter 2026 financial results before market open on Friday, May 8, 2026, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time.

The earnings conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13760143 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days.

The Company also announced its participation in upcoming investor conferences.

On May 18, 2026, the Company will participate in the Wolfe Research Global Consumer Growth Conference being held virtually on May 18, 2026. Management will host a fireside chat presentation at 1:30 p.m. Eastern Time and hold virtual investor meetings throughout the day.

On May 19, 2026, the Company will participate in the 16th Annual LD Micro Invitational being held at the Luxe Sunset Blvd Hotel in Los Angeles on May 19, 2026. Management will host a presentation at 12:30 p.m. Pacific Time and hold investor meetings throughout the day.

The fireside chat presentations at both conferences will be available live and for replay on the Investor Relations page on the company's website at https://investors.elitebodysculpture.com.

About AirSculpt

AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

Investor Contact:

Allison Malkin
Partner, ICR Inc.
AirSculpt@icrinc.com


Risks

  • Uncertainty in financial performance as actual earnings results are yet to be disclosed, impacting investor sentiment in healthcare-related stocks.
  • Dependence on market reception of upcoming earnings and investor presentations could influence stock volatility.
  • External factors such as economic conditions affecting consumer spending on elective body contouring procedures could pose risks to revenue growth.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026